November 03, 2015

Novartis Agrees to Preliminary $390 Million Settlement to Resolve Kickback Case

News reports indicate that Novartis AG reached a tentative agreement with the DOJ to pay $390 million to resolve allegations that it paid rebates to specialty pharmacies in exchange for promoting Novartis pharmaceuticals, including Exjade, Myfortic, Tasigna, Gleevec and TOBI.  At this time, the settlement is reported to be preliminary.  The allegations arose in the context of a qui tam action filed by a former Novartis employee.